
Popular drug appears to protect against heart disease
A Vanderbilt University Medical Center study found that empagliflozin reduced inflammatory monocyte and platelet aggregates in obese women with prediabetes after just two weeks, an effect that increased over three months and was not observed in the low-calorie diet group, suggesting a direct anti-inflammatory effect of the drug beyond weight loss.




















